Skip to content

News

Partner Member Profile: The Blanton-Davis Ovarian Cancer Re...

Partner Member Profile: The Blanton-Davis Ovarian Cancer Research Program, at the University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center is one of the nation’s preeminent hospitals for cancer care. Located in Houston, Texas, MD Anderson’s Blanton-Davis Ovarian Cancer Research Program was created in 1996 as a critical step toward the goal of eradicating ovarian cancer. The program was the nation’s first formal, comprehensive ovarian cancer research … Continued

Community

Ovarian Cancer in African Americans

Ovarian Cancer in African Americans

A new report from the American Cancer Society estimates cancer incidence and mortality rates for African Americans. In the case of ovarian cancer, both incidence and mortality are lower for African American women than for white women. Ovarian cancer incidence for African American women is 74 percent of the rate for white women; death rates … Continued

Research

Stress and Cancer

Stress and Cancer

A new study of mice with prostate cancer indicated that stress can hinder the effectiveness of anti-cancer therapies. In this mouse model, the use of beta-blockers did prevent stress from accelerating cancer growth. The pathway will now be tested in human prostate cells. Read an article about the study here and the journal article here. … Continued

Research

FGFR4 is a Prognostic Marker and Therapeutic Target for Ova...

FGFR4 is a Prognostic Marker and Therapeutic Target for Ovarian Cancer

In the journal Clinical Cancer Research, a group of researchers, including current and past OCRF grantees Anil Sood and Gabriel Lopez-Berestein, evaluated the prognostic value of fibroblast growth factor receptor 4 (FGFR4) protein expression in patients with advanced-stage, high-grade serous ovarian cancer. They found that FGFR4 is a prognostic marker for the disease.  Furthermore, silencing FGFR4 significantly … Continued

Research

Interval Debulking Surgery Appears to Increase Risk of Plat...

Interval Debulking Surgery Appears to Increase Risk of Platinum Resistance

A study of 425 Stage III and IV ovarian cancer patients had either primary debulking surgery or interval debulking surgery. Interval debulking surgery did not appear to increase the risk of initial platinum resistance, but did appear to increase the risk of platinum resistance in the recurrent setting. See the abstract here

Research

Extended Breastfeeding Reduces the Risk of Ovarian Cancer

Extended Breastfeeding Reduces the Risk of Ovarian Cancer

In a study published in the American Journal of Clinical Nutrition, researchers from Curtin University in Australia found that extended breastfeeding significantly reduces the risk of ovarian cancer in women. The study examined 493 Chinese women who had been diagnosed with ovarian cancer. The study found that women who breastfed for more than 13 months were … Continued

Research

High Blood Calcium Levels May Indicate Ovarian Cancer

High Blood Calcium Levels May Indicate Ovarian Cancer

A new study indicates a direct link between higher blood calcium levels and presence of ovarian cancer. Specifically, “women who were later diagnosed with ovarian cancer and women who later died of ovarian cancer had higher levels of calcium in blood than women who did not before their cancer diagnosis.” Read an article about the … Continued

Research

Hormonal Risk & Tumor Aggressiveness

Hormonal Risk & Tumor Aggressiveness

In an analysis of more than 4,000 women with ovarian cancer, it appears that some hormonal and reproductive factors may affect tumor aggressiveness. The study showed that increased age was associated with greater risk of rapidly fatal disease use of oral contraceptives was associated with a decreased risk of rapidly fatal disease increased parity (having … Continued

Research

Phase II Study Shows No Improvement in PFS with Addition of...

Phase II Study Shows No Improvement in PFS with Addition of Pertuzumab

A study of 149 women with platinum sensitive ovarian cancer, half treated with carboplatin and paclitaxel or gemcitabine, half with that treatment plus pertuzumab, showed that the addition of pertuzumab to chemotherapy did not significantly increase progression free survival (PFS). However, the drug was described as “well-tolerated” and did not appear to increase the risk … Continued

Research

Ovarian Cancer Research Fund Awards Over $6 Million in 2013...

Ovarian Cancer Research Fund Awards Over $6 Million in 2013 Grants

OCRF receives record number of research grant applications; launches national patient support program with new educational grants New York, NY January 10, 2013 — Ovarian Cancer Research Fund (OCRF) has awarded over $5.9 million in scientific research grants for ovarian cancer this year. Additionally, two educational and support grants totaling $100,000 were given to new … Continued

OCRA News

Meet OCRF’s 2013 Research Grant Recipients

Meet OCRF’s 2013 Research Grant Recipients

OCRF has awarded nearly $6 million in grants for ovarian cancer research this year. After receiving over 170 applications – the highest number in its history, for the second year in a row – OCRF and its prestigious Scientific Advisory Committee endeavored first and foremost to fund the best science. The Committee evaluated each proposal … Continued

OCRA News

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.